MCL Literature Feed

In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.

This review outlines emerging therapeutic strategies, including non-covalent BTKis, CAR-T, and bispecifics, for managing the clinically challenging population of MCL patients relapsing after covalent BTK inhibitors.

This review highlights using geriatric assessments to guide therapy selection and proactively manage toxicities in older MCL patients, aiming to optimize outcomes and avoid over- or undertreatment.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.

This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.

In mantle cell lymphoma, MRD assessment is most predictive of survival after four induction cycles, while rapid clearance within two cycles offers no prognostic benefit, guiding risk stratification.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

Brexu-cel CAR-T therapy induced a durable 15-month complete remission in a rapidly progressing, relapsed/refractory MCL patient post-BTKi, highlighting its efficacy despite manageable rare cardiovascular toxicities.

A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.

This case report illustrates the efficacy of CAR-T therapy in a relapsed/refractory MCL patient who progressed after both autologous transplant and BTK inhibitor treatment, reinforcing its clinical value.

This case report describes the extremely rare finding of a collision tumor involving extranodal mantle cell lymphoma and a colon adenocarcinoma, highlighting a potential diagnostic and pathological challenge.

Long-term follow-up of the Philemon trial confirms durable responses for the chemotherapy-free triplet of ibrutinib, lenalidomide, and rituximab in relapsed/refractory MCL.

A new flow cytometry score incorporating CD19/CD20 ratio, CD200, and CD43 improves diagnostic sensitivity for differentiating MCL from CLL/SLL, a common and critical clinical challenge.

This modeling study in CLL suggests lower ibrutinib doses (140-280mg) maintain full BTK occupancy, implying potential for dose reduction to manage toxicity in MCL patients without compromising efficacy.

This preclinical CLL study validates 5-lipoxygenase inhibitors for disrupting tumor-microenvironment adhesion, reinforcing this novel mechanism, previously identified by the authors, as a potential therapeutic strategy for MCL.

A new laboratory method was developed to measure pirtobrutinib in rat plasma, providing a foundational tool for preclinical pharmacokinetic studies essential for this BTKi's clinical development.

This review summarizes the genomic, molecular, and pathological variations in MCL, highlighting how this biological heterogeneity impacts risk stratification, prognosis, and the development of personalized therapies.

A cross-validated, lymphoma-tailored NGS panel demonstrates high accuracy, providing a framework for implementing standardized genomic testing for prognostication in routine MCL clinical practice.

This systematic review finds all AI models for lymphoma histopathology, including MCL, have a high risk of bias, questioning their reported high accuracy and current clinical readiness.

A case of TP53-mutated, indolent non-nodal MCL suggests this high-risk marker may not mandate immediate therapy in this specific subtype, supporting a watch-and-wait approach.

This comprehensive review outlines evolving frontline MCL strategies, highlighting the integration of targeted agents, re-evaluation of transplant, and the emerging role of MRD-guided therapy to improve outcomes.

This review details intrinsic (NF-κB, apoptosis, DNA repair) and extrinsic (tumor microenvironment) resistance mechanisms, identifying new therapeutic vulnerabilities to guide personalized strategies for high-risk MCL patients.

This review summarizes current and emerging therapies for relapsed/refractory MCL, highlighting key strategies like BTKi/BCL2i combinations, CAR-T, and bispecific antibodies for this poor-prognosis population.

This review synthesizes clinical, molecular, and genomic markers to define high-risk MCL, guiding risk-stratified treatment and highlighting future therapies like bispecifics for this poor-prognosis population.

This editorial introduces a review series on mantle cell lymphoma, framing the rapid evolution of the treatment landscape from chemotherapy to novel targeted and cellular therapies.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

A rare case of extranodal MCL presenting as bilateral adrenal masses showed avidity on both FDG and DOTATATE PET/CT, expanding the differential diagnosis for adrenal lesions.

This review clarifies that cyclin D1-negative MCL is driven by CCND2 or CCND3 translocations, proposing new terminology to improve diagnostic accuracy for this rare and often missed subtype.

An MCL patient on ibrutinib had persistent COVID-19 missed by nasopharyngeal swabs but diagnosed via bronchoalveolar lavage, underscoring the need for deeper sampling in immunosuppressed patients.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.